Is SS-31 Legal? FDA, Compounding and WADA Status
SS-31's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.
- FDA status
- accelerated approval for Barth syndrome (Sep 2025)
- PCAC vote
- Not reviewed
- not on the Jul 2026 PCAC agenda
- WADA
- Not listed
- 2026 Prohibited List
Current status
FDA accelerated approval for Barth syndrome (Sep 2025)SS-31 is FDA accelerated approval for Barth syndrome (Sep 2025). Products sold as research chemicals are not the approved drug and are not checked by the FDA.
| Country | Status | Source |
|---|---|---|
| United States | ApprovedApproved by FDA as Forzinity (elamipretide), Stealth BioTherapeutics, original approval 19 Sept 2025, under accelerated approval to improve muscle strength in Barth syndrome (label quote). | api.fda.govchecked 2 Oct 2026 |
Timeline
- FDA warning letters to five research-peptide sellersEnforcement
Compounding and research-use sellers
- Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
- The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
- "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.
Sport and drug testing
Not on the WADA Prohibited ListSS-31 (elamipretide) is not named on the list. It received FDA accelerated approval in 2025, so the S0 catch-all does not apply to it.
Outside the US
Rules differ by country. What each regulator's own records show, with the date we checked:
| Country | Status | Source |
|---|---|---|
| United Kingdom | No approved product foundNo approved product found in an emc (UK SmPC compendium) search for "elamipretide (SS-31)" on 2 Oct 2026. | medicines.org.ukchecked 2 Oct 2026 |
| Canada | No approved product foundNo product found in a Health Canada Drug Product Database search for ingredient "elamipretide (SS-31)" on 2 Oct 2026. | health-products.canada.cachecked 2 Oct 2026 |
| Australia | No approved product foundNo approved product found in an ARTG search for "elamipretide (SS-31)" on 2 Oct 2026. | tga.gov.auchecked 2 Oct 2026 |
| European Union | No centrally authorised EU medicine foundEMA medicines list, searched 2 Oct 2026 | ema.europa.euchecked 2 Oct 2026 |
Approved in September 2025 as Forzinity, for one rare disease
Drugs@FDA lists Forzinity (elamipretide) from Stealth BioTherapeutics with an original approval date of 20250919, as a premixed solution at 80 mg/mL.[2]
The label indication is improving muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg, under accelerated approval.[8]
The label says continued approval may depend on verification of clinical benefit in a confirmatory trial, so the approval is conditional.[8]
FDA warning letters that list SS-31
A letter to a seller listed “SS-31” alongside retatrutide, semaglutide, PT-141 and tesamorelin as unapproved new drugs.[9]
The seller's own copy, quoted by FDA, described SS-31 as a mitochondria-targeted peptide studied for its potential to reduce oxidative stress.[9]
A second letter lists the product as “SS-31 (Elamipretide)” among the unapproved new drugs sold by that seller.[10]
Canada
The Health Canada database search for elamipretide returned no active-ingredient records.[4]
Common questions
Is SS-31 FDA approved?
Yes, as Forzinity (elamipretide) for Barth syndrome, under accelerated approval.[8]
Is SS-31 legal to buy?
FDA's August warning letters list SS-31 among products it calls unapproved new drugs. Forzinity is the separate approved prescription product.[9]
Is SS-31 banned by WADA?
No. SS-31 (elamipretide) is not named on the list. It received FDA accelerated approval in 2025, so the S0 catch-all does not apply to it.
SS-31 FDA approval: when?
The Drugs@FDA original approval date is 20250919.[2]
Is elamipretide FDA approved?
Yes; SS-31 and elamipretide are the same molecule, and Forzinity is the approved product.[2]
More on SS-31
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: Approved by FDA as Forzinity (elamipretide), Stealth BioTherapeutics, original approval 19 Sept 2025, under accelerated approval to improve muscle strength in Barth syndrome (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3United Kingdom: No approved product found in an emc (UK SmPC compendium) search for "elamipretide (SS-31)" on 2 Oct 2026.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
- 4Canada: No product found in a Health Canada Drug Product Database search for ingredient "elamipretide (SS-31)" on 2 Oct 2026.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
- 5Australia: No approved product found in an ARTG search for "elamipretide (SS-31)" on 2 Oct 2026.Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
- 6EMA medicines export (centrally authorised medicines) (searched 2 Oct 2026)European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
- 7FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 8FORZINITY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 9Official web pageOfficial web page · web page
- 10Official web pageOfficial web page · web page
Found an error? Report a correction.